Recursion Pharmaceuticals Inc (NASDAQ:RXRX) price on Thursday, March 20, fall -1.52% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $6.48.
A look at the stock’s price movement, the close in the last trading session was $6.58, moving within a range at $6.4 and $6.76. The beta value (5-Year monthly) was 0.845. Turning to its 52-week performance, $12.36 and $5.60 were the 52-week high and 52-week low respectively. Overall, RXRX moved -40.39% over the past month.
Recursion Pharmaceuticals Inc’s market cap currently stands at around $2.60 billion, with investors looking forward to this quarter’s earnings report slated for on 2025-Feb-27.
Analysts have a consensus estimate of 18.12M for the company’s revenue for the quarter, with a low and high estimate of 6M and 34.3M respectively. The average forecast suggests up to a 31.34% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 95.84M, representing a 62.88% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that RXRX is a 100% Sell. On the other hand, the stock is on average a 50% Buy as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
3 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 1 analyst(s) rate the stock as a Hold, 2 recommend RXRX as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
RXRX’s current price about -7.00% and -12.72% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 43.72, while 7-day volatility ratio is 6.80% and 9.88% in the 30-day chart. Further, Recursion Pharmaceuticals Inc (RXRX) has a beta value of 0.89, and an average true range (ATR) of 0.69. Analysts have given the company’s stock an average 52-week price target of $6, forecast between a low of $6 and high of $6. Looking at the price targets, the low is 7.41% off current price level while to achieve the yearly target high, price needs to move 7.41%. Nonetheless, investors will most likely welcome a 7.41% jump to $6 which is the analysts’ median price.
If we refocus on Recursion Pharmaceuticals Inc (NASDAQ:RXRX), historical trading data shows that trading volumes averaged 17.01 over the past 10 days and 23.46 million over the past 3 months. The company’s latest data on shares outstanding shows there are 389.55 million shares.
The 23.93% of Recursion Pharmaceuticals Inc’s shares are in the hands of company insiders while institutional holders own 60.16% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 80.72 million on 2025-02-28, giving us a short ratio of 2.51. The data shows that as of 2025-02-28 short interest in Recursion Pharmaceuticals Inc (RXRX) stood at 2183.0 of shares outstanding, with shares short rising to 63.75 million registered in 2025-01-31. Current price change has pushed the stock -4.14% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the RXRX stock continues to rise going into the next quarter.
